Literature DB >> 11379824

The dorsal root ganglia in adrenomyeloneuropathy: neuronal atrophy and abnormal mitochondria.

J M Powers1, D P DeCiero, C Cox, E K Richfield, M Ito, A B Moser, H W Moser.   

Abstract

Adrenomyeloneuropathy (AMN), a disease of spinal cord, brain, adrenal, and testis, mostly affects men with spastic paraparesis or ataxia beginning in their second or third decade. The spinal cord displays bilateral, usually symmetrical, long tract degeneration particularly of the gracile tract in a "dying-back" pattern. The available data strongly indicate that the fundamental lesion in AMN is an axonopathy or neuronopathy. We compared lumbar dorsal root ganglia (DRG) from 3 AMN patients to 6 age-matched controls histologically, morphometrically, immunohistochemically, and ultrastructurally. There was no apparent neuronal loss, necrosis or apoptosis, nor obvious atrophy; nodules of Nageotte were sparse in both groups. The morphometric studies, however, did reveal neuronal atrophy with a decrease in the number of large neurons and a corresponding increase in neurons less than 2,000 microm2, especially in the 1,500-1,999 microm2 range. No consistent immunohistochemical differences were observed, and no specific cell type appeared to be lost. Many mitochondria in the AMN neurons demonstrated lipidic inclusions; this raises the possibility that, in addition to the well-known peroxisomal defect, impaired mitochondrial function may lead to a failure of ATP-dependent axoplasmic transport in AMN spinal tracts with consequent "dying-back" axonal degeneration. The observation that the DRG parent neurons of the degenerate gracile tracts in AMN undergo atrophy and do not display appreciable evidence of cell death, even at autopsy, provides a wide window of opportunity for the development of therapeutic strategies to combat or prevent this myeloneuropathy.

Entities:  

Mesh:

Year:  2001        PMID: 11379824     DOI: 10.1093/jnen/60.5.493

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  18 in total

Review 1.  Evaluation of therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser; Ali Fatemi; Kathleen Zackowski; Seth Smith; Xavier Golay; Larry Muenz; Gerald Raymond
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

Review 2.  Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis.

Authors:  Inderjit Singh; Aurora Pujol
Journal:  Brain Pathol       Date:  2010-07       Impact factor: 6.508

Review 3.  Normal and defective neuronal membranes: structure and function: neuronal lesions in peroxisomal disorders.

Authors:  J M Powers
Journal:  J Mol Neurosci       Date:  2001 Apr-Jun       Impact factor: 3.444

Review 4.  X-linked adrenoleukodystrophy: pathogenesis and treatment.

Authors:  Marc Engelen; Stephan Kemp; Bwee-Tien Poll-The
Journal:  Curr Neurol Neurosci Rep       Date:  2014-10       Impact factor: 5.081

5.  Restless Legs Syndrome in X-linked adrenoleukodystrophy.

Authors:  John W Winkelman; Natalie R Grant; Francine Molay; Christopher D Stephen; Reza Sadjadi; Florian S Eichler
Journal:  Sleep Med       Date:  2022-02-16       Impact factor: 4.842

Review 6.  Therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser
Journal:  NeuroRx       Date:  2006-04

Review 7.  "Lorenzo's oil" therapy for X-linked adrenoleukodystrophy: rationale and current assessment of efficacy.

Authors:  Hugo W Moser; Ann B Moser; Kim Hollandsworth; N Hong Brereton; Gerald V Raymond
Journal:  J Mol Neurosci       Date:  2007-09       Impact factor: 3.444

8.  Role of ALDP (ABCD1) and mitochondria in X-linked adrenoleukodystrophy.

Authors:  M C McGuinness; J-F Lu; H-P Zhang; G-X Dong; A K Heinzer; P A Watkins; J Powers; K D Smith
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

Review 9.  Redox interplay between mitochondria and peroxisomes.

Authors:  Celien Lismont; Marcus Nordgren; Paul P Van Veldhoven; Marc Fransen
Journal:  Front Cell Dev Biol       Date:  2015-05-27

Review 10.  Pathophysiology of X-linked adrenoleukodystrophy.

Authors:  J Berger; S Forss-Petter; F S Eichler
Journal:  Biochimie       Date:  2013-12-04       Impact factor: 4.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.